The brochures, application notes, webinars, downloads, videos, and other resources in this section will help you get the most out of your Sensititre MIC plate or Oxoid disc testing system.
Oleksiuk M, Screen J, Scopes E, Bursens J. Evaluation of Thermo Scientific Sensititre Susceptibility MIC plates for the MIC determination of Gram negative isolates for amoxicillin, amoxicillin/clavulanic acid, cefotaxime, meropenem and piperacillin-tazobactam. Poster presentation, 2015. Full text
Jayol A, Nordmann P, André C, Poirel L, Dubois V. Evaluation of three broth microdilution systems to determine colistin susceptibility of Gram-negative bacilli. J Antimicrob Chemother. 2018; 73: 1272-1278. PubMed
Åhman J, Matuschek E, Kahlmeter G. The quality of antimicrobial discs from nine manufacturers—EUCAST evaluations in 2014 and 2017. Clin Microbiol Infect. 2019; 25: 346-352. Full text
Åhman J, Matuschek E, Kahlmeter G. EUCAST evaluation of 21 brands of Mueller–Hinton dehydrated media for disc diffusion testing. Clin Microbiol Infect. 2020; 26: 1412.e1-1412.e5. Full text
Healthcare professionals use Sensititre AST systems in their labs every day. Here’s what some of them have to say.
Hear how the Sensititre System is supporting informed treatment decisions at the University of Michigan Hospital and Health System from Jerod Nagel, PharmD, BCPS (AQID), Clinical Specialist, Infectious Diseases.
Customers will be notified our updates to SWIN Software for their Sensititre Systems. For questions or to request updates, contact your sales representative or Technical Support.
Education resources for AST include an abundance of free online materials on testing methods, antimicrobial resistance (AMR), and antimicrobial stewardship.
For training courses taught at your site and online, see the Services tab.
As communicated in December 2023 and effective January 2024, clinical laboratories performing antimicrobial susceptibility testing (AST) will be required to use breakpoints currently recognized by Clinical and Laboratory Standards Institute (CLSI) and/or US Food and Drug Administration (FDA) as required by both the College of American Pathologists (CAP) and the Clinical Laboratory Improvement Amendments (CLIA).
The business has now concluded a thorough review of our AST portfolio and has modified panels, as required, to comply with the FDA susceptibility test interpretive criteria (STIC) or ‘breakpoint’ ranges for which Thermo Fisher Scientific has gained FDA clearance. If necessary, updated panel formats have been re-designed to comply with the breakpoint ranges, as well as include new antimicrobials to provide more testing options to your laboratory.
Please refer to the below issued letters which outline affected standard panels and required actions, including availability dates and timeline for discontinuation of impacted formats.